Clinical trials: Pharmakokinetic
Healthy
Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg
This was a randomized, single-blind, two-period, two sequence cross-over study under fasting condition, with a one-week wash-out period, to compare the pharmacokinetic profiles and bioavailability of two formulations (the test…
- Trial name
- NCT02518451
- Testing
- Valsartan 160 mg film-coated caplets (test formulation), Valsartan 160 mg film-coated caplets (reference formulation)
- Where
- Indonesia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Pharmakokinetic
A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin
The primary purpose of this study is to determine whether the treatment with AZD1981 affect the exposure of Warfarin.
- Trial name
- NCT01199341
- Testing
- AZD1981, Warfarin
- Where
- Sweden
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pain
Single Dose Pharmacokinetics of Egalet® Hydrocodone
The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet® hydrocodone formulations and compare to a marketed hydrocodone drug.
- Trial name
- NCT00802087
- Testing
- hydrocodone, hydrocodone & acetaminophen combination
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Egalet Ltd
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
- Trial name
- NCT01549769
- Testing
- Bardoxolone Methyl
- Volunteers
- 24 people
- Sponsor
- Biogen
Periodontitis
A Safety/Tolerability and Pharmakokinetic Study of Sargramostim Administrated in the Gingiva
This exploratory study is the first study in a clinical program where the overall objective is to develop a novel pharmaceutical therapy comprising local administration of GM-CSF for the treatment of periodontitis.
- Trial name
- NCT00689143
- Testing
- sargramostim
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Innoventus Project AB
Inflammatory Bowel Disease
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
- Trial name
- NCT01213680
- Testing
- Monofer (iron isomaltoside 1000), Monofer
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Pharmakokinetic, Open Label
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
TNX-102 SL has recently been approved by the United States (US) Food and Drug Administration (FDA) under the brand name TONMYA for the treatment of fibromyalgia.
- Conditions
- Pharmakokinetic, Open Label, Phase 1
- Trial name
- NCT07413367
- Testing
- TNX-102 SL Tablet
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tonix Pharmaceuticals, Inc.
Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
The primary objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of A4250 after single or multiple oral doses in healthy subjects.
- Conditions
- Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome
- Trial name
- NCT02963077
- Testing
- A4250, CRC (A3384), Questran
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Albireo